Bone BiologicsBBLG
13F holders, Q1 2026 (March 31)3holders −4
0new positions
4sold out
$1.10avg. 13F price*
At the end of Q1 2026, 3 institutions reported holding Bone Biologics Corp. (BBLG) in their 13F filings, down 4 from Q4 2025. 0 opened new positions and 4 sold out. The largest holders were Tower Research Capital LLC (TRC) ($5K), SBI Securities Co., Ltd. ($253) and UBS Group AG ($62).
- Company
- Bone Biologics Corp.
- CUSIP
- 098070600
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 4 | $66K |
All 13F filers, Q4 2025 → Q1 2026: 747 shares bought and 47,409 shares sold, net −46,662 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Tower Research Capital LLC (TRC) | 0.00% | Add +22.1% | 4,126 | $5K |
| SBI Securities Co., Ltd. | 0.00% | No change | 230 | $253 |
| UBS Group AG | 0.00% | Reduce -97.1% | 56 | $62 |
"% of holder's portfolio" is BBLG's weight in each manager's 13F, not the share of Bone Biologics Corp. the manager owns.